CA2567477A1 - Combinaison d'ondes radio et de substances pharmaceutiquement actives - Google Patents

Combinaison d'ondes radio et de substances pharmaceutiquement actives Download PDF

Info

Publication number
CA2567477A1
CA2567477A1 CA002567477A CA2567477A CA2567477A1 CA 2567477 A1 CA2567477 A1 CA 2567477A1 CA 002567477 A CA002567477 A CA 002567477A CA 2567477 A CA2567477 A CA 2567477A CA 2567477 A1 CA2567477 A1 CA 2567477A1
Authority
CA
Canada
Prior art keywords
cancer
inhibitors
carcinoma
tumors
radio waves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002567477A
Other languages
English (en)
Inventor
Jochen Kalbe
Georg Ludwig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004028156A external-priority patent/DE102004028156A1/de
Application filed by Individual filed Critical Individual
Publication of CA2567477A1 publication Critical patent/CA2567477A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une combinaison d'ondes radio et de substances pharmaceutiquement actives sélectionnées dans le groupe comprenant a) des anticorps monoclonaux et/ou b) des inhibiteurs de tyrosine kinase et/ou c) des inhibiteurs d'angiogénèse et/ou d) des inhibiteurs de farnésyl transférase et/ou e) des inhibiteurs de topoisomérase-I ou -II et/ou f) de la cytokine et/ou g) des oligonucléotides antisens, cette combinaison pouvant éventuellement comporter un ou plusieurs produits de chimiothérapie. La présente invention porte également sur l'utilisation de cette combinaison pour le traitement prophylactique et/ou thérapeutique du cancer, de tumeurs et de métastases.
CA002567477A 2004-06-09 2005-06-09 Combinaison d'ondes radio et de substances pharmaceutiquement actives Abandoned CA2567477A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004028156.4 2004-06-09
DE102004028156A DE102004028156A1 (de) 2004-06-09 2004-06-09 Kombination von Radiowellen mit pharmakologisch aktiven Substanzen
US58506104P 2004-07-06 2004-07-06
US60/585,061 2004-07-06
PCT/DE2005/001028 WO2005120638A1 (fr) 2004-06-09 2005-06-09 Combinaison d'ondes radio et de substances pharmaceutiquement actives

Publications (1)

Publication Number Publication Date
CA2567477A1 true CA2567477A1 (fr) 2005-12-22

Family

ID=34971290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002567477A Abandoned CA2567477A1 (fr) 2004-06-09 2005-06-09 Combinaison d'ondes radio et de substances pharmaceutiquement actives

Country Status (4)

Country Link
EP (1) EP1753507A1 (fr)
JP (1) JP2008537489A (fr)
CA (1) CA2567477A1 (fr)
WO (1) WO2005120638A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257410B2 (en) * 2006-02-03 2012-09-04 The Catholic University Of America Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237898A (en) * 1978-03-27 1980-12-09 Critical Systems, Inc. Apparatus for heating tissue and employing protection against transients
JPS55160720A (en) * 1979-05-29 1980-12-13 Mochida Pharmaceut Co Ltd Remedial composition for cancer and its remedial device
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
WO2000057951A1 (fr) * 1999-03-26 2000-10-05 Flock Stephen T Administration de composes pharmaceutiques et recuperation de biomolecules par energie electromagnetique et utilisation
US6853864B2 (en) * 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles

Also Published As

Publication number Publication date
EP1753507A1 (fr) 2007-02-21
WO2005120638A8 (fr) 2007-01-18
WO2005120638A1 (fr) 2005-12-22
JP2008537489A (ja) 2008-09-18

Similar Documents

Publication Publication Date Title
US20070184020A1 (en) Combination of radio waves with pharmacologically active substances
ES2899954T3 (es) Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1
US20190216903A1 (en) Methods of cytotoxic gene therapy to treat tumors
ES2435727T3 (es) Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores
RU2745999C1 (ru) Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии
EP2703001A1 (fr) Vaccination anti-tumorale
US20060178387A1 (en) Combined treatment with capecitabine and an epidermal growth factor receptor kinase inhibitor
MXPA06014002A (es) Tratamiento con cisplatina y un inhibidor de cinasa del receptor del factor de crecimiento epidermico (egfr).
KR20210095868A (ko) 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료
EP3042669A1 (fr) Agent antitumoral et promoteur de l'effet antitumoral
Vuky et al. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer
CA2567477A1 (fr) Combinaison d'ondes radio et de substances pharmaceutiquement actives
JP2011504926A (ja) Ｅｇｆｒキナーゼ阻害剤とｃ−ｋｉｔ阻害剤による併用治療
MX2013009062A (es) Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
KR20230163440A (ko) 멀티 키나제 억제제의 병용 응용
Kitamura et al. Local administration of monoclonal antibody-drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer
WO2021182574A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
US6589981B2 (en) Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
WO2023095929A1 (fr) Agent pour le traitement de tumeurs malignes
US20210214428A1 (en) Immune checkpoint therapy
KR20240038596A (ko) 앱스코팔 효과를 갖는, 암의 예방 또는 치료용 조성물 및 이를 이용한 암의 예방 또는 치료방법
US20220362580A1 (en) Device, apparatus and method for minibeam radiation therapy
RU2778812C2 (ru) Abx196 для применения при лечении рака мочевого пузыря
Białczyk et al. Abscopal effect in solid tumors. Potential mechanisms, application of radioimmunotherapy, and a review of exemplary clinical cases
Lahm et al. Growth inhibition of human colorectal carcinomas by a monoclonal antibody directed against the IGF-I-receptor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090609

FZDE Discontinued

Effective date: 20090609